A Phase I/ II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer.

Trial Profile

A Phase I/ II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Luminespib (Primary) ; Lapatinib; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 01 May 2012 Actual initiation date (1 Jul 2011) added as reported by ClinicalTrials.gov.
    • 01 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top